NCT06758544RecruitingPhase 1/2
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 17 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 2 Jan 2025
- Start date
- 17 Mar 2025
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Guangdong Provincial People's Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT06758544
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 18
- From 17 Mar 2025 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with other oncolytic virus or systemic therapy for pancreatic cancer.
- Previous allogeneic hematopoietic stem cell transplantation or organ transplantation.
- Known alcohol or drug dependency.
Other
- Immunocompromised patients.
- Women who are pregnant or breastfeeding.
Who the study is looking for
- Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures.
- Males and females at 18-75 years of age, inclusive, at the Screening Visit.
- Have a clinical diagnosis of pancreatic cancer.
- An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
- Expected survival time of≥6 months.
- No serious hematologic and cardiac abnormalities of the liver, kidneys, or coagulation functions.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guangdong Provincial People's Hospital Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.